title: Synergistic effect of low dose cyclosporine A and human interleukin 10 overexpression on acute rejection in rat lung allotransplantation.
abstract: OBJECTIVE
  Electroporation mediated transfer of plasmid DNA into peripheral muscle results in high transfection efficiency. The aim of this study was to investigate the effect of gene transfer of human IL-10 (hIL-10) into the tibialis anterior muscle (MTA) in combination with low dose Cyclosporine A (CsA) on acute rejection of lung allografts in the rat.
  
  
  METHODS
  Lung allotransplantation was performed from male BN donor to male Fisher F344 rats. Gene transfer was achieved by intramuscular injection into the MTA of the recipient followed by electroporation (4 x 20 ms impulses at 200 V/cm) 24 h prior to the transplantation. Group A (n=5) received CsA (2.5 mg/kg bw ip) for 5 days post-transplant and group B (n=5) 2.5 microg of PCIK hIL-10 (plasmid expression vector containing human CMV immediate early gene promoter and enhancer) and a low dose CsA (2.5 mg/kg bw i.p.). Graft function was assessed by blood gas at day 5 after exclusion of the native lung. Animals were sacrificed and blood was drawn to measure serum hIL-10 levels (ELISA) and tissue was sampled for histological grading of rejection.
  
  
  RESULTS
  Local expression of hIL-10 was confirmed at the mRNA level by in situ hybridization. All group A control animals showed severe signs of rejection. At day 5 all grafts in group B showed good gas exchange mean PaO2 233+/-123 mmHg, vs 44+/-8 mmHg in group A. Histological examination revealed moderate to severe rejection in all animals in group A (IIIB, ISHLT) in contrast to low moderate rejection in group B (II-IIIA). hIL-10 serum levels on day 5 were 14+/-7 pg/ml in group B vs. 0 in group A.
  
  
  CONCLUSIONS
  Electroporation mediated hIL-10 overexpression in a peripheral muscle of the recipient in combination with low dose CsA reduces acute rejection in this model of rat lung allotransplantation.
authors.affiliation: Division of General Thoracic Surgery, University Hospital, CH-3010 Bern, Switzerland.
authors.forename: Jaroslaw
authors.initials: J
authors.lastname: Pierog
authors.forename: Amiq
authors.initials: A
authors.lastname: Gazdhar
authors.forename: Uz
authors.initials: U
authors.lastname: Stammberger
authors.forename: Matthias
authors.initials: M
authors.lastname: Gugger
authors.forename: Steven
authors.initials: S
authors.lastname: Hyde
authors.forename: Iacob
authors.initials: I
authors.lastname: Mathiesen
authors.forename: Tomasz
authors.initials: T
authors.lastname: Grodzki
authors.forename: Ralph A
authors.initials: RA
authors.lastname: Schmid
mesh_terms: D000208:Acute Disease; D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004357:Drug Synergism; D018274:Electroporation / Q000379:methods; D015870:Gene Expression; D018014:Gene Transfer Techniques; D006084:Graft Rejection / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007273:Injections, Intramuscular; D016753:Interleukin-10 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D016040:Lung Transplantation / Q000276:immunology; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D011916:Rats, Inbred F344; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D016753:Interleukin-10; D016572:Cyclosporine